ALK-Abelló A/S

Stocks

ALK B

DK0061802139

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 17/07/2026 BST			5-day change	1st Jan Change
240.00 ^DKK	-1.07%		-1.07%	+4.99%

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT

Transcript : ALK-Abelló A/S, Q1 2026 Earnings Call, May 04, 2026

Published on 05/04/2026 at 10:05 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Per Plotnikof (Executives)

Hello, everyone, and welcome to this presentation of ALK's Q1 results. Thank you all for joining us. Let's turn to Slide #2 with an introduction to the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about ALK-Abelló A/S

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT
05-28	Berenberg Starts ALK-Abelló at Buy on Growth Potential Amid Food Allergy Market Entry Plans	MT
05-04	ALK-Abelló A/S, Q1 2026 Earnings Call, May 04, 2026
05-04	ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	ALK-Abelló Upgrades FY26 Revenue Outlook	MT
05-04	Alk-Abello Q1 Ebit up at DKK 570 million	RE
05-04	Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026	CI
04-20	ALK-Abelló Reports Positive Results from Mid-stage Trial of Peanut Allergy Treatment	MT
04-20	ALK-Abello announces successful outcome of phase 2 trial of peanut allergy tablet	RE
04-20	ALK Announces Successful Outcome of Phase 2 Trial with Its Tablet for Treatment of Peanut Allergy Demonstrating Early Onset of Efficacy	CI
04-15	ALK-Abelló Receives Approval to Sell Needle-Free Anaphylaxis Treatment in Canada	MT
04-15	Alk-Abello says Neffy approved in Canada	RE
04-15	ALK-Abelló A/S Receives Approval For Neffy 2 Mg As Needle-Free Anaphylaxis Treatment In Canada	CI
03-31	Alk-Abello says EURneffy 1 mg approved across the EU	RE